| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deglutition | 6 | 2021 | 221 | 1.080 |
Why?
|
| Deglutition Disorders | 5 | 2021 | 297 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2021 | 624 | 0.640 |
Why?
|
| Head and Neck Neoplasms | 6 | 2021 | 561 | 0.630 |
Why?
|
| Breast Neoplasms | 8 | 2019 | 1533 | 0.610 |
Why?
|
| Respiratory Mechanics | 1 | 2016 | 33 | 0.570 |
Why?
|
| Respiration | 1 | 2016 | 91 | 0.550 |
Why?
|
| Mouth Neoplasms | 3 | 2021 | 206 | 0.470 |
Why?
|
| Caregivers | 3 | 2019 | 365 | 0.370 |
Why?
|
| Oncogenes | 2 | 2022 | 71 | 0.370 |
Why?
|
| Barium | 3 | 2020 | 52 | 0.370 |
Why?
|
| Survivors | 4 | 2015 | 254 | 0.350 |
Why?
|
| Skin Neoplasms | 3 | 2019 | 375 | 0.350 |
Why?
|
| Aged | 25 | 2021 | 14842 | 0.340 |
Why?
|
| Neoplasms | 4 | 2022 | 1660 | 0.340 |
Why?
|
| Pharynx | 3 | 2020 | 89 | 0.340 |
Why?
|
| Neuropilin-2 | 2 | 2020 | 19 | 0.330 |
Why?
|
| Cancer Survivors | 3 | 2019 | 145 | 0.330 |
Why?
|
| Female | 37 | 2021 | 38015 | 0.320 |
Why?
|
| Middle Aged | 27 | 2021 | 21119 | 0.320 |
Why?
|
| Humans | 51 | 2022 | 68525 | 0.310 |
Why?
|
| Liposomes | 2 | 2018 | 107 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 331 | 0.300 |
Why?
|
| Fever | 2 | 2018 | 96 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 467 | 0.290 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 1172 | 0.290 |
Why?
|
| Patient Compliance | 3 | 2019 | 402 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 756 | 0.280 |
Why?
|
| Lymph Nodes | 3 | 2012 | 258 | 0.280 |
Why?
|
| Contrast Media | 3 | 2019 | 594 | 0.280 |
Why?
|
| Population Surveillance | 2 | 2019 | 285 | 0.270 |
Why?
|
| Needs Assessment | 2 | 2019 | 185 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 300 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 444 | 0.260 |
Why?
|
| Male | 28 | 2021 | 37281 | 0.250 |
Why?
|
| Cell Line, Tumor | 9 | 2022 | 1849 | 0.250 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 439 | 0.250 |
Why?
|
| Fluoroscopy | 3 | 2021 | 152 | 0.240 |
Why?
|
| Mammography | 2 | 2019 | 310 | 0.240 |
Why?
|
| Quality of Life | 5 | 2019 | 1515 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 332 | 0.230 |
Why?
|
| Adult | 19 | 2020 | 21375 | 0.230 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 4843 | 0.230 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 66 | 0.230 |
Why?
|
| Carcinoma | 2 | 2016 | 215 | 0.220 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 560 | 0.210 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 61 | 0.210 |
Why?
|
| Acid Ceramidase | 2 | 2013 | 85 | 0.210 |
Why?
|
| Receptors, Estrogen | 2 | 2019 | 142 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 369 | 0.200 |
Why?
|
| Lysophospholipids | 2 | 2013 | 209 | 0.200 |
Why?
|
| Bacteroides fragilis | 1 | 2021 | 20 | 0.200 |
Why?
|
| Video Recording | 2 | 2019 | 145 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 86 | 0.190 |
Why?
|
| Indazoles | 1 | 2020 | 12 | 0.190 |
Why?
|
| Cell Cycle Proteins | 2 | 2019 | 230 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 28 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1070 | 0.190 |
Why?
|
| Sphingosine | 2 | 2013 | 315 | 0.190 |
Why?
|
| Deoxycytidine | 1 | 2020 | 83 | 0.190 |
Why?
|
| Acrylamides | 1 | 2020 | 12 | 0.190 |
Why?
|
| Aniline Compounds | 1 | 2020 | 52 | 0.190 |
Why?
|
| Immunotherapy | 2 | 2020 | 212 | 0.180 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 16 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2020 | 141 | 0.180 |
Why?
|
| Hematologic Tests | 1 | 2019 | 24 | 0.180 |
Why?
|
| Quinazolines | 1 | 2019 | 70 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 41 | 0.180 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.180 |
Why?
|
| Temperature | 2 | 2018 | 340 | 0.170 |
Why?
|
| Th17 Cells | 1 | 2020 | 116 | 0.170 |
Why?
|
| Community Health Workers | 1 | 2019 | 32 | 0.170 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 121 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2016 | 135 | 0.170 |
Why?
|
| Survivorship | 1 | 2019 | 20 | 0.170 |
Why?
|
| Psychology | 1 | 2018 | 36 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2019 | 99 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 163 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2019 | 190 | 0.160 |
Why?
|
| Algorithms | 2 | 2022 | 1194 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 265 | 0.160 |
Why?
|
| Colonoscopy | 1 | 2019 | 156 | 0.160 |
Why?
|
| Immunoglobulin Km Allotypes | 1 | 2018 | 34 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 799 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 245 | 0.160 |
Why?
|
| Piperazines | 1 | 2019 | 206 | 0.160 |
Why?
|
| Circadian Clocks | 1 | 2017 | 1 | 0.160 |
Why?
|
| Mouth | 1 | 2018 | 64 | 0.160 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 99 | 0.160 |
Why?
|
| Barium Sulfate | 1 | 2018 | 66 | 0.160 |
Why?
|
| Papillomaviridae | 1 | 2018 | 87 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 467 | 0.160 |
Why?
|
| ErbB Receptors | 1 | 2019 | 239 | 0.160 |
Why?
|
| Phosphoproteins | 1 | 2019 | 202 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 214 | 0.160 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 149 | 0.160 |
Why?
|
| Glycation End Products, Advanced | 1 | 2018 | 125 | 0.160 |
Why?
|
| Inpatients | 1 | 2019 | 208 | 0.160 |
Why?
|
| Osteosarcoma | 1 | 2017 | 35 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2017 | 49 | 0.150 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 92 | 0.150 |
Why?
|
| Immunoglobulin Gm Allotypes | 1 | 2018 | 103 | 0.150 |
Why?
|
| Receptors, IgG | 1 | 2018 | 94 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 411 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2018 | 231 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 100 | 0.150 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2017 | 40 | 0.150 |
Why?
|
| Plethysmography | 1 | 2016 | 17 | 0.150 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 53 | 0.150 |
Why?
|
| Lung Volume Measurements | 1 | 2016 | 19 | 0.150 |
Why?
|
| Young Adult | 8 | 2020 | 5708 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 61 | 0.140 |
Why?
|
| Health Education | 1 | 2019 | 279 | 0.140 |
Why?
|
| Esophagus | 1 | 2018 | 303 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 46 | 0.140 |
Why?
|
| Keratinocytes | 1 | 2016 | 68 | 0.140 |
Why?
|
| Life Style | 1 | 2018 | 338 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 778 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2021 | 2356 | 0.140 |
Why?
|
| Motivational Interviewing | 1 | 2016 | 40 | 0.140 |
Why?
|
| Psychotherapy, Group | 1 | 2016 | 55 | 0.140 |
Why?
|
| Electromyography | 1 | 2016 | 184 | 0.140 |
Why?
|
| Veterans Health | 1 | 2016 | 61 | 0.140 |
Why?
|
| Genotype | 1 | 2018 | 785 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 79 | 0.140 |
Why?
|
| Melanoma, Experimental | 1 | 2016 | 95 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2021 | 714 | 0.140 |
Why?
|
| Fluoroquinolones | 1 | 2016 | 49 | 0.130 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 209 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 131 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 138 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 1 | 2015 | 219 | 0.130 |
Why?
|
| Urinary Bladder | 2 | 2012 | 108 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.130 |
Why?
|
| Physicians | 2 | 2015 | 324 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2014 | 26 | 0.120 |
Why?
|
| Animals | 11 | 2021 | 20877 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 429 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2017 | 384 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 384 | 0.120 |
Why?
|
| Social Support | 1 | 2017 | 423 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 170 | 0.120 |
Why?
|
| Mice | 7 | 2021 | 8472 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2018 | 617 | 0.120 |
Why?
|
| Health Services Research | 1 | 2015 | 209 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 30 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 27 | 0.120 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 39 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 35 | 0.120 |
Why?
|
| Breast Diseases | 1 | 2013 | 40 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2015 | 368 | 0.120 |
Why?
|
| Hospitalization | 1 | 2019 | 977 | 0.120 |
Why?
|
| Sphingolipids | 2 | 2013 | 337 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 36 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 150 | 0.110 |
Why?
|
| Propanolamines | 1 | 2013 | 70 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 299 | 0.110 |
Why?
|
| Cystitis | 1 | 2012 | 18 | 0.110 |
Why?
|
| Amides | 1 | 2013 | 86 | 0.110 |
Why?
|
| Simvastatin | 1 | 2012 | 34 | 0.110 |
Why?
|
| Urodynamics | 1 | 2012 | 43 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2017 | 447 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 57 | 0.110 |
Why?
|
| Melanoma | 1 | 2016 | 335 | 0.110 |
Why?
|
| Phosphorylation | 3 | 2020 | 1199 | 0.110 |
Why?
|
| Risk Factors | 6 | 2018 | 5719 | 0.110 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 129 | 0.110 |
Why?
|
| Organs at Risk | 1 | 2012 | 9 | 0.110 |
Why?
|
| Tissue Expansion Devices | 1 | 2011 | 2 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2012 | 53 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2012 | 33 | 0.110 |
Why?
|
| Rectum | 1 | 2012 | 62 | 0.100 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2012 | 65 | 0.100 |
Why?
|
| Sarcoma | 1 | 2012 | 70 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 442 | 0.100 |
Why?
|
| Brachytherapy | 1 | 2012 | 79 | 0.100 |
Why?
|
| Mammaplasty | 1 | 2011 | 41 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2019 | 3702 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 432 | 0.100 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 69 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 2790 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 475 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 445 | 0.100 |
Why?
|
| Cell Movement | 3 | 2020 | 630 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 212 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 729 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2018 | 1615 | 0.090 |
Why?
|
| Smoking | 1 | 2018 | 1449 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 951 | 0.090 |
Why?
|
| Apoptosis | 1 | 2016 | 1640 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 508 | 0.090 |
Why?
|
| Ceramides | 1 | 2013 | 578 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2021 | 7028 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2323 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 226 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 510 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1548 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2016 | 1032 | 0.080 |
Why?
|
| Heterografts | 2 | 2017 | 70 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2016 | 1341 | 0.070 |
Why?
|
| United States | 5 | 2019 | 7335 | 0.070 |
Why?
|
| Lung | 1 | 2011 | 849 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 595 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2022 | 2688 | 0.070 |
Why?
|
| Adolescent | 5 | 2018 | 8903 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 349 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 304 | 0.070 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 236 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 536 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1173 | 0.070 |
Why?
|
| Nanoparticles | 2 | 2018 | 254 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 3256 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 1032 | 0.060 |
Why?
|
| SEER Program | 2 | 2014 | 150 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 1054 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2022 | 21 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 27 | 0.050 |
Why?
|
| Depression | 2 | 2019 | 942 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1465 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 17 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2077 | 0.050 |
Why?
|
| Isoantigens | 1 | 2021 | 26 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2550 | 0.050 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 33 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2021 | 120 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 274 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 63 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2798 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 614 | 0.050 |
Why?
|
| South Carolina | 2 | 2019 | 2750 | 0.050 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2020 | 15 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 57 | 0.050 |
Why?
|
| A549 Cells | 1 | 2020 | 50 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 35 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 260 | 0.050 |
Why?
|
| Proteolysis | 1 | 2020 | 97 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 532 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 107 | 0.040 |
Why?
|
| Everolimus | 1 | 2019 | 26 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 132 | 0.040 |
Why?
|
| Thiophenes | 1 | 2019 | 76 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 37 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 852 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 71 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 54 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 260 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 80 | 0.040 |
Why?
|
| Respiratory Aspiration | 1 | 2019 | 13 | 0.040 |
Why?
|
| Child | 3 | 2016 | 6400 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 78 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2019 | 128 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2020 | 330 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 110 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 196 | 0.040 |
Why?
|
| Viscosity | 1 | 2018 | 72 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2018 | 62 | 0.040 |
Why?
|
| Brazil | 1 | 2018 | 48 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 306 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2020 | 791 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 2018 | 32 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 199 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 135 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 118 | 0.040 |
Why?
|
| Biological Transport | 1 | 2018 | 210 | 0.040 |
Why?
|
| ARNTL Transcription Factors | 1 | 2017 | 6 | 0.040 |
Why?
|
| Light Signal Transduction | 1 | 2017 | 6 | 0.040 |
Why?
|
| Photoperiod | 1 | 2017 | 11 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2018 | 93 | 0.040 |
Why?
|
| CLOCK Proteins | 1 | 2017 | 7 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2019 | 200 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 331 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 235 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.040 |
Why?
|
| Microsurgery | 1 | 2018 | 46 | 0.040 |
Why?
|
| Dogs | 1 | 2018 | 490 | 0.040 |
Why?
|
| Heating | 1 | 2017 | 13 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2017 | 70 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2018 | 199 | 0.040 |
Why?
|
| Transfection | 1 | 2019 | 782 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 2017 | 67 | 0.040 |
Why?
|
| Food | 1 | 2017 | 52 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2017 | 99 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2017 | 282 | 0.040 |
Why?
|
| L-Selectin | 1 | 2016 | 28 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 301 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 122 | 0.040 |
Why?
|
| Emotions | 1 | 2018 | 244 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 238 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 230 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2016 | 30 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2014 | 7264 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 948 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2016 | 151 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2018 | 652 | 0.040 |
Why?
|
| Prostatitis | 1 | 2016 | 10 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 100 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 266 | 0.030 |
Why?
|
| Necrosis | 1 | 2016 | 239 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 434 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 447 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 866 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 329 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 481 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 241 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 672 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 489 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 955 | 0.030 |
Why?
|
| Phenotype | 1 | 2018 | 946 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 710 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1265 | 0.030 |
Why?
|
| Medicine | 1 | 2015 | 51 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 730 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 901 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 1082 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 954 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 113 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2264 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 125 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 2093 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 71 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 61 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 118 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 705 | 0.030 |
Why?
|
| Maryland | 1 | 2013 | 77 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1037 | 0.030 |
Why?
|
| Health Surveys | 1 | 2015 | 488 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 329 | 0.030 |
Why?
|
| Urination | 1 | 2012 | 19 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 294 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Urine | 1 | 2012 | 47 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1851 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 911 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 226 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 284 | 0.030 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2012 | 8 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2012 | 11 | 0.030 |
Why?
|
| Psychometrics | 1 | 2015 | 514 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 63 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 36 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2011 | 3 | 0.030 |
Why?
|
| Fiducial Markers | 1 | 2012 | 10 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 791 | 0.030 |
Why?
|
| Pressure | 1 | 2012 | 252 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 1692 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2012 | 210 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.030 |
Why?
|
| Mastectomy | 1 | 2011 | 56 | 0.030 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 422 | 0.030 |
Why?
|
| Cetuximab | 1 | 2011 | 19 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2017 | 659 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1046 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 163 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 242 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 770 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 191 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1027 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 523 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 929 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 160 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 303 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 151 | 0.020 |
Why?
|
| Endosonography | 1 | 2011 | 177 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 682 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 766 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1582 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2011 | 419 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 880 | 0.020 |
Why?
|
| Veterans | 1 | 2016 | 904 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 2175 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 2083 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1419 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 2891 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 3185 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 5300 | 0.020 |
Why?
|